Marco Antonio de Avila Vitoria

Dr. Marco Antonio de Avila Vitoria

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2010 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
RGReuben Granich
Reuben Granich
SCSiobhan Crowley
Siobhan Crowley
MVMarco Antonio de Avila Vitoria
Marco Antonio de Avila Vitoria
YLYing‐Ru Lo
Ying‐Ru Lo
YSYves Souteyrand
Yves Souteyrand
BWBrian Williams
Brian Williams
In 2007 an estimated 33 million people were living with HIV; 67% resided in sub-Saharan Africa, with 35% in eight countries alone. In 2007, there were about 1.4 million HIV-positive tuberculosis cases. Globally, approximately 4 million people had been given highly active antiretroviral therapy (HAART) by the end of 2008, but in 2007, an estimated 6.7 million were still in need of HAART and 2.7 million more became infected with HIV.

1 June 2009 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
MVMarco Antonio de Avila Vitoria
Marco Antonio de Avila Vitoria
RGReuben Granich
Reuben Granich
CGCharles Gilks
Charles Gilks
CGChristian Gunneberg
Christian Gunneberg
MHMehran Hosseini
Mehran Hosseini
KCKevin M. De Cock
Kevin M. De Cock
HIV/AIDS, tuberculosis, and malaria are 3 major global public health threats and cause substantial morbidity, mortality, negative socioeconomic impac

26 March 2020 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
NFNathan Ford
Nathan Ford
MVMarco Antonio de Avila Vitoria
Marco Antonio de Avila Vitoria
ARAjay Rangaraj
Ajay Rangaraj
SNSusan L Norris
Susan L Norris
ACAlexandra Calmy
Alexandra Calmy
MDMeg Doherty
Meg Doherty
Introduction: Several antiretroviral drugs are being considered for the treatment of COVID‐19, the disease caused by a newly identified coronavirus, (SARS‐CoV‐2). We systematically reviewed the clinical outcomes of using antiretroviral drugs for the prevention and treatment of coronaviruses and planned clinical trials.Methods: Three databases were screened from inception to 30 March 2020 for studies reporting clinical outcomes of patients with SARS, MERS or COVID‐19 treated with antiretrovirals.Results: From an initial screen of 433 titles, two randomized trials and 24 observational studies provided clinical outcome data on the use of antiretroviral drugs; most studies reported outcomes using LPV/r as treatment. Of the 21 observational studies reporting treatment outcomes, there were three studies among patients with SARS, six studies among patients with MERS and 12 studies among patients with COVID‐19. In one randomized trial 99 patients with severe COVID‐19 illness were randomized to receive LPV/r (400/100 mg twice a day) and 100 patients to standard of care for 14 days: LPV/r was not associated with a statistically significant difference in time to clinical improvement, although LPV/r given within 12 days of symptoms was associated with shorter time to clinical improvement; 28 day mortality was numerically lower in the LPV/r group (14/99) compared to the control group (25/100), but this difference was not statistically significant. The second trial found no benefit. The certainty of the evidence for the randomized trials was low. In the observational studies 3 out of 361 patients who received LPV/r died; the certainty of evidence was very low. Three studies reported a possible protective effect of LPV/r as post‐exposure prophylaxis. Again, the certainty of the evidence was very low due to uncertainty due to limited sample size.Conclusions: On the basis of the available evidence it is uncertain whether LPV/r and other antiretrovirals improve clinical outcomes or prevent infection among patients at high risk of acquiring COVID‐19.

28 May 2021 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
PDF file
EPErica Parker
Erica Parker
MJMelinda A. Judge
Melinda A. Judge
EMEusebio Macete
Eusebio Macete
TNTacilta Nhampossa
Tacilta Nhampossa
JDJienchi Dorward
Jienchi Dorward
PSPeter N. Le Souëf
Peter N. Le Souëf
The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.

1 January 2013 in Current Opinion in HIV and AIDS
Verified
Journal Article
Closed access
MVMarco Antonio de Avila Vitoria
Marco Antonio de Avila Vitoria
SVStefano Vella
Stefano Vella
NFNathan Ford
Nathan Ford
This review describes the evolution of WHO guidelines for antiretroviral therapy (ART) in HIV-infected individuals, considering the key epidemiological, scientific, programmatic, and political changes over the last decade, and highlights the major trends for the management of the HIV disease in future guidelines revisions. In the last few years, new evidence has emerged supporting the potential preventive benefit of ART in reducing HIV transmission. This, together with the potential clinical benefits of earlier initiation of therapy, has led to the consideration of the broader strategic use of ART, taking into account the clinical and public health benefit, and programmatic feasibility. In 2002, WHO established its first guidelines for ART use, primarily focused on a public health approach for resource-limited settings. These recommendations were updated in 2003, 2006, and 2010, incorporating progressive changes reflecting progressive increase in the knowledge of HIV pathogenesis, development of new drugs and diagnostics, and increased experience of HIV treatment and prevention programs. The impact of several international political commitments and scale-up initiatives such as the 3 by 5 Initiative, Universal Access targets, and the Treatment 2.0 Strategy were also important drivers of the global response, increasing the treatment coverage and catalyzing the necessary environment for the establishment of operational and programmatic components for an expanded and sustainable global response to HIV/AIDS.

26 August 2014 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
DÉDidier K. Ékouévi
Didier K. Ékouévi
Boris Kevin TchoungaBoris Kevin Tchounga
Boris Kevin Tchounga
PCPatrick A Coffie
Patrick A Coffie
JTJoseph Tegbe
Joseph Tegbe
ABAlexandra Bitty-Anderson
Alexandra Bitty-Anderson
SESerge P Eholie
Serge P Eholie
Few data are available on antiretroviral therapy (ART) response among HIV-2 infected patients. We conducted a systematic review on treatment outcomes among HIV-2 infected patients on ART, focusing on the immunological and virological responses in adults. Data were extracted from articles that were selected after screening of PubMed/MEDLINE up to November 2012 and abstracts of the 1996–2012 international conferences. Observational cohorts, clinical trials and program reports were eligible as long as they reported data on ART response (clinical, immunological or virological) among HIV-2 infected patients. The determinants investigated included patients’ demographic characteristics, CD4 cell count at baseline and ART received. Seventeen reports (involving 976 HIV-2 only and 454 HIV1&2 dually reactive patients) were included in the final review, and the analysis presented in this report are related to HIV-2 infected patients only. There was no randomized controlled trial and only two cohorts had enrolled more than 100 HIV-2 only infected patients. The median CD4 count at ART initiation was 165 cells/mm3, [IQR; 137–201] and the median age at ART initiation was 44 years (IQR: 42–48 years). Ten studies included 103 patients treated with three nucleoside reverse transcriptase inhibitors (NRTI). Protease inhibitor (PI) based regimens were reported by 16 studies. Before 2009, the most frequent PIs used were Nelfinavir and Indinavir, whereas it was Lopinavir/ritonavir thereafter. The immunological response at month-12 was reported in six studies and the mean CD4 cell count increase was +118 cells/μL (min-max: 45–200 cells/μL). Overall, clinical and immuno-virologic outcomes in HIV-2 infected individuals treated with ART are suboptimal. There is a need of randomized controlled trials to improve the management and outcomes of people living with HIV-2 infection.